TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
61.70
+1.17 (1.93%)
At close: Dec 20, 2024, 4:00 PM
62.00
+0.30 (0.49%)
After-hours: Dec 20, 2024, 7:55 PM EST
TransMedics Group Revenue
TransMedics Group had revenue of $108.76M in the quarter ending September 30, 2024, with 63.72% growth. This brings the company's revenue in the last twelve months to $401.09M, up 109.09% year-over-year. In the year 2023, TransMedics Group had annual revenue of $241.62M with 158.53% growth.
Revenue (ttm)
$401.09M
Revenue Growth
+109.09%
P/S Ratio
5.08
Revenue / Employee
$686,798
Employees
584
Market Cap
2.07B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
Dec 28, 2019 | 23.60M | 10.59M | 81.33% |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 30, 2006 | Pro | Pro | Pro |
Dec 31, 2005 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PACS Group | 3.56B |
Alignment Healthcare | 2.47B |
Premier | 1.33B |
Omnicell | 1.06B |
NeoGenomics | 644.12M |
Beam Therapeutics | 349.64M |
GeneDx Holdings | 267.23M |
LeMaitre Vascular | 213.03M |
TMDX News
- 9 days ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 17 days ago - TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024 - Seeking Alpha
- 18 days ago - TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - PRNewsWire
- 18 days ago - Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 19 days ago - TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook - PRNewsWire
- 25 days ago - TransMedics to Host Investor & Analyst Day on December 10, 2024 - PRNewsWire
- 4 weeks ago - TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference - PRNewsWire
- 4 weeks ago - TransMedics: Long-Term Thesis Hasn't Changed At All - Seeking Alpha